Chiron Corporation

Novartis Vaccines & Diagnostics, Gmbh

Ortho-clinical Diagnostics, Inc

Grifols Worldwide Operations Limited

David Y Chien

Angelica Medina-Selby

Doris Guenzi Coit

Laura Tandeske

Mark J Selby

Michael Houghton

Qui-Lim Choo

George Kuo

John M Polo

Robert L Warne

Pablo D T Valenzuela

Jian Zheng

Jang Hyun Han

Amy J Weiner

Phillip M Arcangel

Kevin R Shoemaker

Wanda Zeigler

Stephen Tirell

John Andrew Hall

John J Donnelly

Carlos George-Nascimento

Yiu-Lian Fong

Phillip Arcangel

Sergio Abrignani

Alexander Gyenes

Edward Glazer

Toshiya Fujihara

Azita Tabrizi

Heather Todd

Sansan Lin

Bruce Phelps

Sergio Pichuantes

Charles A Harrington

Mark David VanCleve

William Andrews

Yiu-Lan Fong

Mark David Van Cleve

Stephen Coates

Celine Hu

Susan Hilt

Nicholas Valiante

Vega Masignani

Carlos George-Nasciemento

Charles Harrington

Stephen R Coates

Konrad Stadler

Mi Young Seo

Jens-Peter Gregersen

Rino Rappuoli

Hyun Chul Song

Hans Dieter Klenk

Lin Sansan

Modified hepatitis C virus polypeptides are described. The polypeptides include the HCV NS4a domain and modified NS3 domain. The polypeptides retain conformational epitopes. HCV immunoassays including the polypeptides are also described.

HCV NS4a/modified NS3 polypeptides and uses thereof

HCV NS4A/modified NS3 polypeptides and uses thereof

Recombinant production of immunogenic West Nile Virus (WNV) proteins is described. These proteins, heterodimers comprising the proteins, fusions thereof, polynucleotides encoding the proteins, and combinations thereof, as well as antibodies produced therefrom, can be used in immunogenic compositions for preventing, treating and diagnosing WNV infection. Also described are highly sensitive ELISA and strip immunoassay methods for detecting the presence of WNV in biological samples.

Immunogenic reagents from west nile virus

Reagents, methods and immunodiagnostic test kits for the accurate detection of hepatitis B virus (HBV) infection are disclosed. The methods and kits employ novel rabbit monoclonal antibodies directed against HBV surface antigens (HBsAg) with mutations in the 'a' determinant region of HBsAg.

Rabbit monoclonal antibodies to hepatitis B surface antigens and methods of using the same

Modified HCV multiple epitope fusion antigens (MEFAs) are described. The proteins include modified sequences such that proteolytic cleavage of the MEFAs by HCV NS3 protease is inhibited. HCV immunoassays including the modified MEFAs are also described.

HCV multiple epitope fusion antigens with modified proteolytic cleavage sites and uses thereof

A device for in-line blood screening and testing using biochips is disclosed. The screening methods include nucleic acid amplification techniques and antibody/antigen assays to detect target molecules and agents indicative of infectious diseases or metabolic diseases.

Device and method for in-line blood testing using biochips

Modified HCV non-structural proteins are described. The proteins include modified NS3 domains such that proteolytic activity of the NS3 molecule is inhibited. The modified proteins retain conformational epitopes. HCV immunoassays including the modified NS3 molecules are also described.

HCV non-structural protein mutants and uses thereof

A polypeptide containing an anchor region, a protease recognition site, and a detectable signal region can be produced recombinantly and directly attached to a solid support. The polypeptide is useful for screening protease regulators, especially protease inhibitors.

Protease regulator screening assay

Methods for obtaining recombinantly produced, C-terminally truncated, E1 and E2 polypeptides from cell lysates are disclosed. The intracellularly expressed truncated molecules display improved biological properties as compared to their secreted counterparts.

Intracellular production of hepatitis C E1 and E2 truncated polypeptides

The invention relates to a method of detecting HCV infection in a biological sample, the method comprising providing an immunoassay solid support, comprising an HCV anti-core antibody, an antigen comprising an HCV NS3/4epitope, and an HCV multiple epitope fusion antigen, that can detect both HCV antigens and antibodies present in a sample. The invention also includes polynucleotides encoding multiple epitope fusion antigens for use in the assay, recombinant vectors and host cells comprising such polynucleotides, and methods of producing the multiple epitope fusion antigens.

Polynucleotides encoding a multiple epitope fusion antigen for use in an HCV antigen/antibody combination assay

HCV immunoassays comprising an NS3/4a conformational epitope and a multiple epitope fusion antigen are provided, as well as immunoassay solid supports for use with the immunoassays.

Immunoassays for anti-HCV antibodies

An HCV antigen/antibody/antigen assay is provided. The assay employs an isolated first antigen from a region of the HCV polyprotein, and an HCV multiple epitope fusion antigen that includes an epitope from the same region of the polyprotein as the first antigen. Both the first antigen and the multiple epitope fusion antigen bind antibodies present in an HCV-infected sample.

HCV assay

Immunoassays for detecting hepatitis C virus protein and immune complexes between hepatitis C virus protein and antibodies in biological samples, methods of screening blood products for hepatitis C virus, and kits employed therefor are provided.

Hepatitis C viral antigen immunoassay detection systems

Multiple epitope fusion proteins and immunoassays using the same are disclosed. The multiple epitope fusion proteins are encompassed by the general structural formula (A)&#x2212;(B)&#x2212;Cwhich represents a linear amino acid sequence, wherein B is an amino acid sequence of an epitope or cluster of epitopes and each B contains at least five and not more than 1,000 amino acids, y is an integer of 2 or more, A and C are each independently an amino acid sequence of an epitope or cluster of epitopes not adjacent to B in nature and x and z are each independently an integer of 0 or more wherein at least one of x and z is 1 or more.

Multiple epitope fusion protein

Growing community of inventors

Alamo, CA, United States of America

David Y Chien